Science Letter
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Science Letter
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Alzheimer Disease Vaccine
Effects of A-beta immunization in patients with AD in an interrupted trial
July 12th, 2005
Scientists describe the clinical effects of A-beta immunization (AN1792) in patients with Alzheimer disease in an interrupted trial in a recent issue of the journal Neurology. According to a study from the United States, "AN1792 (beta-amyloid [A-beta] 1-42) immunization reduces A-beta plaque burden and preserves cognitive function in APP transgenic mice. The authors report the results of a phase IIa immunotherapy trial of AN1792(QS-21) in patients with mild to moderate Alzheimer disease (AD) that was interrupted because of meningo-encephalitis in 6% of immunized patients. "This randomized, multicenter, placebo-controlled, double-blind trial of...
Source: Science Letter (2005-07-12)
|
